deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT05199285

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Sponsor: Academic and Community Cancer Research United

Conditions BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma Locally Advanced Hepatocellular Carcinoma Metastatic Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8 Unresectable Hepatocellular Carcinoma
Interventions Ipilimumab Nivolumab
Updated 13 times since 2022 Last updated: Sep 30, 2025 Started: Jan 19, 2023 Primary completion: Sep 4, 2025 Completion: Sep 4, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor has withdrawn support for the study.

Other terminated trials from Academic and Community Cancer Research United

See all terminations from Academic and Community Cancer Research United

Other BCLC Stage B Hepatocellular Carcinoma trials with similar outcome

Browse all BCLC Stage B Hepatocellular Carcinoma trials

This PHASE2 trial investigates BCLC Stage B Hepatocellular Carcinoma and BCLC Stage C Hepatocellular Carcinoma and is currently terminated or withdrawn. Academic and Community Cancer Research United leads this study, which shows 13 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

13 versions recorded

  1. Nov 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Oct 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 8 earlier versions

  1. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  2. Apr 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

  5. Sep 2022 — Jan 2023 [monthly]

    Not Yet Recruiting PHASE2

  6. Apr 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  7. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

  8. Feb 2022 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations